Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Researchers in the US have developed an artificial intelligence algorithm that can sift through electronic health records ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

This 18th-20th February, 2025, London will host the premier HR event for European Life Sciences. Join CHROs, CPOs, and HR ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...